Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. CEO and President John Cox reported an automatic sale of 2,732 shares of common stock on March 5, 2026 at $14.90 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024 under a pre-established Rule 10b5-1 “binding contract,” so the sale is not described as a discretionary trade.
After this transaction, Cox directly holds 374,145 shares of common stock, which the filing states includes 279,895 unvested RSUs. In addition, 18,000 shares are held in each of four separate trusts for the benefit of a child of the reporting person, reported as indirect ownership positions.
Dyne Therapeutics reports a Schedule 13G/A from T. Rowe Price Investment Management showing beneficial ownership of 26,578,437 shares of common stock, representing 16.2% of the class.
The filing shows sole voting power for 26,223,470 shares and sole dispositive power for 26,578,437. The filing includes a statement denying beneficial ownership by T. Rowe Price Investment Management. The form is signed by Ellen York on 03/06/2026.
DYN submitted a Rule 144 notice reporting planned transactions in its common stock. The filing lists 9,081 Restricted Stock Units described as "Equity Compensation" with a 03/04/2026 date and identifies Stifel Nicolaus & Company Inc as the broker. The filing also records a prior sale by John Cox of 2,662 common shares on 12/05/2025 for $55,150.00.
Dyne Therapeutics reported fourth quarter and full year 2025 results alongside major clinical progress in its neuromuscular pipeline. Year-end cash, cash equivalents and marketable securities were $1.1 billion, which the company expects will fund operations into the first quarter of 2028.
For 2025, research and development expenses were $398.3 million and general and administrative expenses were $69.9 million, leading to a net loss of $446.2 million, or $3.47 per share, compared with a $317.4 million loss in 2024. In the DELIVER trial for Duchenne muscular dystrophy, z‑rostudirsen achieved 5.46% of normal dystrophin at six months with statistically significant change from baseline and showed improvements on multiple functional measures with a favorable safety profile.
The company plans to submit a BLA for U.S. Accelerated Approval of z‑rostudirsen in Q2 2026 and targets a potential U.S. launch in Q1 2027, assuming Priority Review and approval. Dyne also advances z‑basivarsen in DM1 toward a Phase 3 trial in March 2026 and expects enrollment completion of the ACHIEVE registrational expansion cohort in Q2 2026.
Dyne Therapeutics outlines its strategy to develop targeted genetic medicines for neuromuscular diseases using its FORCE antibody‑oligonucleotide platform. Lead candidates z‑rostudirsen for Duchenne muscular dystrophy and z‑basivarsen for myotonic dystrophy type 1 are in global Phase 1/2 trials designed to support U.S. Accelerated Approval and confirmatory Phase 3 studies.
The company is also advancing programs for facioscapulohumeral dystrophy and Pompe disease, plus earlier discovery assets in CNS, skeletal, cardiac and metabolic muscle disorders. It reports an aggregate non‑affiliate equity value of about $948 million as of June 30, 2025 and 165,027,119 shares outstanding as of February 27, 2026.
Dyne Therapeutics CEO and President John Cox reported new equity awards in the company’s stock. On February 12, 2026, he received 180,000 shares of common stock in the form of restricted stock units that vest quarterly over four years starting May 12, 2026.
He was also granted a stock option for 285,000 shares of common stock at an exercise price of $16 per share, vesting in equal monthly installments over four years through February 12, 2030. Following these awards, he directly beneficially owns 376,877 shares of common stock, which include unvested RSUs.
Additional holdings of 18,000 shares of common stock in each of four separate trusts are reported as indirect ownership, with each trust held for the benefit of a child of the reporting person.
Dyne Therapeutics Chief Medical Officer Kerr Douglas reported new equity awards in the company. On February 12, 2026, Douglas received 85,000 shares of Common Stock in the form of restricted stock units, bringing direct beneficial ownership of Common Stock to 172,510 shares, including 156,625 unvested RSUs.
Douglas was also granted a stock option for 130,000 shares of Common Stock at an exercise price of $16 per share. The option is scheduled to vest in equal monthly installments over four years through February 12, 2030, while the RSUs vest quarterly over four years starting May 12, 2026.
Dyne Therapeutics Chief Commercial Officer Johanna Friedl-Naderer reported new equity awards in the company’s stock. On February 12, 2026, she received 60,000 shares of Common Stock in the form of restricted stock units at a price of $0 per share, bringing her directly owned Common Stock to 154,729 shares, including 132,152 unvested RSUs.
She was also granted a stock option for 90,000 shares of Common Stock at an exercise price of $16 per share. This option vests in equal monthly installments over four years through February 12, 2030, while the RSUs vest quarterly over four years starting May 12, 2026.
Dyne Therapeutics’ Chief Financial Officer Erick Lucera received new equity awards. On February 12, 2026, Lucera was granted 65,000 restricted stock units, each representing one share of common stock, at a grant price of $0. These RSUs are scheduled to vest in equal quarterly installments over four years starting May 12, 2026.
On the same date, Lucera also received a stock option covering 105,000 shares of common stock with an exercise price of $16 per share. This option vests in equal monthly installments over four years through February 12, 2030. Following the RSU grant, Lucera directly beneficially owns 131,100 unvested RSUs.
Janus Henderson Group plc reported its beneficial ownership of common stock of Dyne Therapeutics Inc. as of December 31, 2025. Through its investment adviser subsidiaries managing client accounts, it may be deemed to beneficially own 13,887,722 Dyne Therapeutics shares, representing 8.5% of the class.
The Janus Henderson asset managers hold shared power to vote and dispose of these shares, with no sole voting or dispositive power. The economic benefits, including dividends and sale proceeds, belong to the underlying managed portfolios, and Janus Henderson disclaims ownership of those rights.